Navigation Links
Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide

e="float:right; position: relative;">

"We are pleased that these results complement our previous study with linaclotide in patients suffering from chronic constipation," said Mark Currie, Ph.D., Microbia's senior vice president of research and development. "These data greatly expand our understanding of the potential beneficial actions of linaclotide in patients with lower bowel dysfunction and provide an impetus to advance this agent in later stage clinical development."

About Linaclotide

Linaclotide is a first-in-class compound currently being tested for the treatment of IBS-C, CC and other gastrointestinal disorders. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. In preclinical testing linaclotide was shown to increase fluid secretion into the intestine, accelerate intestinal transit, and decrease visceral pain. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. In Phase 1 testing linaclotide was well tolerated and was not detected in the systemic circulation of healthy subjects. Linaclotide is currently being studied in a pair of Phase 2 dose- ranging trials for IBS-C and CC.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. Patients with IBS often have altered patterns of gastrointestinal motility which contribute to symptoms. Colonic transit that is too rapid results in diarrhea, while delayed colonic transit results in constipation. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Health care costs associated with IBS exceed $25 billion annually. IBS patients fall into three subgroups-constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and alternating (IBS-A)-and 30% to 40% of these patients suffer from IBS-C.
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/9/2009)...Va., Nov. 9 TessArae® LLC, a ...lications, announces the launch of new integrated ...ions that underlie human hereditary diseases. The...-based resequencing with novel nucleotide sequence...les screening for all targeted mutations in multip...
(Date:11/9/2009)...f., Nov. 9 Women,s sexual health c...s name to Viveve as it prepares for a 2010 launch ...kets. ,, "Viveve is a name that we believe capt...exual health," said Kerry Pope, Viveve,s president...purpose of helping women restore their sense of fu...
(Date:11/9/2009)... Va., Nov. 9 LifeNet Health, a lea...launch of Vertigraft Cervical Bio-Implant (VG2C) w...4; is a new, proprietary glycerol-based preservati...be stored in a fully hydrated state at ambient tem...eeze-dry bio-implants, doing away with lengthy tha...
Breaking Medicine Technology:TessArae Delivers Lower Cost Option to Genetic Testing Market 2Women's Sexual Health Company Changes Name in Preparation for Market Entry 2LifeNet Health Announces First Bio-Implant with New Preservation Technology 2Angiotech Pharmaceuticals announces FDA approval of TAXUS 28R 29 Liberte 28R 29 Long Stent 13067 1Angiotech Pharmaceuticals announces FDA approval of TAXUS 28R 29 Liberte 28R 29 Long Stent 13067 2Angiotech Pharmaceuticals announces FDA approval of TAXUS 28R 29 Liberte 28R 29 Long Stent 13067 3Angiotech Pharmaceuticals announces FDA approval of TAXUS 28R 29 Liberte 28R 29 Long Stent 13067 4Angiotech Pharmaceuticals announces FDA approval of TAXUS 28R 29 Liberte 28R 29 Long Stent 13067 5Anthem Blue Cross and Blue Shield in New Hampshire Gives Boost to Help Small Businesses in the Granite State 51933 1Anthem Blue Cross and Blue Shield in New Hampshire Gives Boost to Help Small Businesses in the Granite State 51933 2Anthem Blue Cross and Blue Shield in New Hampshire Gives Boost to Help Small Businesses in the Granite State 51933 3House Health Reform Bill Would Deliver on President Obamas Vision Says Campaign for Americas Future 51930 1
...dure; Pediatrics becomes 4th, surgical specialty ...HD instruments, CUPE...nounced the successful completion of the first ped...instruments. The patient, an 8-year-old boy,from S...his surgery was,sitting up in his hospital bed pla...
...nsaturated fatty acids (PUFAs), mainly the omega-3..., immune function and total parenteral,nutrition (...er electronic,publications summarize new findings ...greater amounts of docosahexaenoic acid,(DHA), an ...A, to preterm,infants with very low birth weights ...
Other Medicine Technology:Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments 2Omega-3 Fatty Acids Critical to Infants, Mothers and the Seriously Ill 2
(Date:11/9/2009)... 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the gl...nounced the availability of INTUNIV (guanfacine) E...nited States for the treatment of Attention-Defici...olescents ages 6 to 17. INTUNIV, a once-daily for...cheduled alpha-2A receptor agonist approved for th...
(Date:11/9/2009)...ple around the world suffer from cataracts. Thomas...his coauthors discuss cataract surgery with the im...sue of Deutsches rzteblatt International ( Dtsch...ndness is usually due to opacification of the lens...rations are performed each year. Cataracts can be ...
(Date:11/9/2009)... people have tried to read Charles Darwin,s "Origi...0th anniversary this month, but gave up. , For t...k is about, help by way of a new book is at hand. ...eznick is the author of "The Origin Then and N...s " (Princeton University Press, 2009), which mak...
(Date:11/9/2009)...n bias might be the reason why African Americans a...e same rate as similar patients in other racial gr...pancreas transplantation at Georgetown University ...rgetown University Medical Center, and colleagues ...he American Journal of Transplantation . , Med...
(Date:11/9/2009)...risks, but not all agree , , MONDAY, Nov...ine solution might have soothing short-term benefi...nfections in the long run by stripping your nose o...ose, we are removing the bad mucus but, unfortunat...ains the antimicrobial agents as well," said Dr. T...
Breaking Medicine News(10 mins):Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 3Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 4Health News:Book by UC Riverside biologist explains Darwin's 'Origin of Species' 2Health News:Physician bias might keep life-saving transplants from black and Hispanic patients 2Health News:Sinus Rinses May Do More Harm Than Good 2Health News:Sinus Rinses May Do More Harm Than Good 3
...s begun the second reading of the controversial Me...t's third attempt in eight years to reform the 198...sting legislation on the matter to ensure that pat...hospital will be subject to community treatment or...
...e Group (AMARRG), Dr David Rivett, today congratul...e extension of emergency// medical training as par...and providing more support for GPs to participate....ns on an otherwise positive initiative. The...
...e sources, is touted as a more eco-friendly fuel, ... widespread// use of ethanol could actually pose a... fuel, may not be that eco-friendly after all. The...tmospheric scientist Mark Z. Jacobson says that if...
...ations portraying overall statistics of patients r.../. ART for AIDS has certainly reached many, though...e left out. As per the recent figures, it is...mparison with the figures of last year, there has ...
...ollections of liver tissue samples ever acquired b...esearchers have embarked on a massive study// of o...lcoholic fatty liver disease starts with the accum...lly fatal cirrhosis. If the damage becomes too gre...
...in Florida, USA, a 61-year-old woman caught shopli...e queue to pay her bill as she was suffering from ...able bowel syndrome seems to have been discovered ...d when she was caught shoplifting in Cape Coral, F...
Other Medicine News:Health News:UK Mental Health Reforms Will Do More Harm Than Good, Critics Warn 2Health News:Government Delivers On Emergency Medical Training For Rural Doctors 2Health News:Ethanol Could Be Damaging for Human Health, New Study Says 2Health News:Ethanol Could Be Damaging for Human Health, New Study Says 3Health News:Geisinger Launches Extensive Study on Obesity and Related Liver Problem 2
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: